Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Advancing stroke care with cutting-edge ultrasound biomarkers for Neurocritical Care

Project description

Ultrasound biomarkers for stroke treatment

The effective imaging of strokes is crucial for diagnosis, but current tools often limit bedside care. The Resolve Stroke (RS) project aims to address these challenges with the development of SYLVER, a point-of-care ultrasound system that uses 100 % raw data and advanced algorithms. This system enhances stroke management and introduces novel biomarkers, such as RS-LVO (Large Vessel Occlusion) and RS-USP (Ultrasound Perfusion Score). These offer insights similar to computed tomography (CT) scans but with the added benefits of ultrasound technology. The EU-funded RS-NeuroMarkers project will focus on developing, validating, and integrating RS-LVO and RS-USP into the SYLVER system. The validation aims to confirm the efficacy of these biomarkers in real-world bedside applications.

Objective

Today, the lack of effective imaging kills. Early diagnosis can cure most deadly diseases, and stroke is a prime example. With one in four adults likely to experience a stroke, timely detection is crucial. Unfortunately, current imaging tools fall short for bedside diagnosis, wasting valuable time both in ambulances and at the patient’s bedside. To implement widespread screening and advanced therapies, to provide a diagnosis at the right time and thus save lives, we would need to increase the accessibility of CT scans and MRIs by 100-fold and drastically improve their limitations. The solution lies in enhancing ultrasound, a portable and accessible imaging modality.

At Resolve Stroke, we are unlocking ultrasound's full potential with SYLVER, our innovative point-of-care ultrasound system powered by Software-Based Ultrasound technologies. SYLVER harnesses 100% of raw ultrasound data to deliver life-saving insights through advanced 3D algorithms and imaging. By combining ultrasound with advanced post-processing algorithms, SYLVER expands the boundaries of what ultrasound can achieve. Key opinion leaders are already identifying new critical applications for our technologies, extending beyond neurology into fields like oncology, to monitor tumor aggressiveness, and transplant vascularization.

With access to this new ultrasound data, novel ultrasound-based biomarkers, such as RS-LVO (Large Vessel Occlusion detection) and RS-USP (Ultrasound Perfusion Score), have the potential to revolutionize stroke management and brain care. These biomarkers offer critical, quantitative insights comparable to those obtained through CT scans, but with the added benefits of the ultrasound modality.

EIC support will enable us to develop, validate, and integrate RS-LVO and RS-USP into the SYLVER system, with validation in both laboratory and clinical settings to confirm their efficacy in real-world applications, at patient’s bedside.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-TRANSITION-01

See all projects funded under this call

Coordinator

RESOLVE STROKE SAS
Net EU contribution
€ 2 493 436,60
Address
107 RUE DU CHERCHE MIDI
75006 Paris
France
SME
Yes
Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data